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The sheep genome harbors20 copies of endogenous retroviruses
(enJSRVs) closely related to the exogenous and oncogenic Jaag-
siekte sheep retrovirus (JSRV). One of the enJSRV loci, enJS56A1,
has a defect for viral exit. We report a previously uncharacterized
mechanism of retroviral interference. The defect possessed by
enJS56A1 is determined by its Gag protein and is transdominant
over the exogenous JSRV. By electron microscopy, cells transfected
by enJS56A1, with or without JSRV, show agglomerates of tightly
packed intracellular particles most abundant in the perinuclear
area. The defect in exit and ability to interfere with JSRV exit could
be largely attributed to the presence of tryptophan, rather than
arginine, at position 21 of enJS56A1 Gag; C98 and V102 also
contribute to these properties. We found that enJS56A1 or similar
loci containing W21, C98, and V102 are expressed in sheep endo-
metrium. enJS56A1 is a previously unrecognized example of a
naturally occurring endogenous retrovirus expressing a dominant
negative Gag acting at a late step of the viral replication cycle.
Understanding the late blockade exerted by enJS56A1 could un-
ravel fundamental aspects of retroviral biology and help to devise
new antiretroviral strategies.
Endogenous retroviruses (ERVs) are fixed in the genome ofvirtually all vertebrates and are transmitted by simple Men-
delian rules. With rare exceptions, ERVs are noninfectious
and nonpathogenic, whereas their exogenous counterparts are
infectious and frequently pathogenic (1). It is likely that ERVs
have provided some advantage to the evolution of their hosts,
given the long time periods of their association (1). A possible
biological role hypothesized for ERVs is to help the host resist
infections of pathogenic exogenous retroviruses, affording
a selective advantage to the host bearing them. For instance,
some avian and murine ERVs can block infection of related
exogenous retroviruses at entry by receptor interference; mouse
Fv-1 blocks infection at a preintegration step, also can be viewed
as an ERV (1).
In this study, we have investigated a previously uncharacter-
ized interference mechanism between endogenous and exoge-
nous betaretroviruses of sheep. Sheep are an outbred animal
species with 20 copies of highly expressed endogenous bet-
aretroviruses (enJSRVs) (2), which are related to the exogenous
and pathogenic Jaagsiekte sheep retrovirus (JSRV). JSRV is the
causative agent of ovine pulmonary adenocarcinoma, a trans-
missible lung cancer of sheep (3, 4). JSRV is a lung-tropic
retrovirus, whereas enJSRVs are expressed at high levels in the
epithelial cells of most of the genital tract of the ewe (5–7).
At present, no effective cell culture system for the propagation
of JSRV exists, most likely because the JSRV long terminal
repeat is specifically expressed in type II pneumocytes and Clara
cells (8). These differentiated epithelial cells are difficult to
isolate and lose their phenotype quickly once in culture. We have
previously overcome this problem by developing a JSRV infec-
tious molecular clone under the control of the cytomegalovirus
(CMV) immediate early promoter (pCMV2JS21). Abundant
quantities of WT JSRV are produced upon transfection of 293T
with pCMV2JS21; virus collected in the supernatant is able to
induce lung adenocarcinoma in experimentally infected lambs
(3). In contrast, the endogenous enJS56A1 locus in the same
expression system (pCMV2en56A1) is unable to release viral
particles in the supernatant of 293T transfected cells, despite the
presence of intact ORFs in its gag, pol, and env genes (7).
Expression of enJSRV Env protein blocks entry of JSRV by
receptor interference (9). In this paper, we show evidence for a
second block exhibited by enJS56A1 toward the exogenous
JSRV that is exerted at a late step of the retroviral replication
cycle, more precisely after assembly. The block is determined
mainly by a single mutation near the N terminus of the Gag
protein. Understanding the mechanisms of retroviral interfer-
ence is important to unravel fundamental aspects of retrovirus
biology and evolution and also to devise new antiretroviral
strategies (10).
Materials and Methods
Plasmids. pCMV2JS21 and pCMV2en56A1 express, respectively,
the exogenous JSRV21 molecular clone and the endogenous
enJS56A1 locus under the control of the CMV immediate early
promoter (3, 7). To derive the chimeras described below, we
obtained the plasmid pJS21m, which is derived by pCMV2JS21
through the removal of the multiple cloning site after the 3 long
terminal repeat and introduction of an XbaI site (at Gag amino
acid 88) and a SalI site (Gag amino acid 142) by silent mutagen-
esis. The nomenclature of the chimeras, e.g., p30–344eBx, is
based on numbers indicating the relative amino acid residues
position of Gag introduced (30–344) from enJS56A1 (e) in the
backbone (B) of the exogenous JSRV (x). Positions refer to the
JSRV21 Gag (3). Chimeras pGePEx and pGxPEe are described
in ref. 7 and are referenced in this paper for uniformity,
respectively, as p1–344eBx and p1–344xBe. p88–142ebBx and
p88–142ecBx have the endogenous portion of the chimeras
respectively from the endogenous loci enJS5F16 and enJS59A1
(7). p88–142eBx derives from p88–142eBx, where amino acid
residues AVPEGVKSD (enJS56A1 Gag residues 120–128) have
been replaced by PPPPP of the corresponding JSRV region.
pJS21Prol derives from pJS21m where amino acid residues
PPPPP (JSRV Gag residues 121–125) have been replaced by the
residues EGVKS in the corresponding region of enJS56A1.
pJS21pro has a deletion of the pro gene from position 2116 to
2147 (positions refer to nucleotide sequence of JSRV21) (3).
Mutants with single or double mutations have been obtained by
using the QuikChange Site-Directed Mutagenesis kit (Strat-
agene). Mutants are indicated by the name JS or en56, depend-
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ing on whether they derive from pJS21m or pCMV2enJS56A1,
followed by a letter indicating the amino acid residue mutated,
the position of the residue in Gag, and the letter of the newly
introduced amino acid; multiple mutations are separated by a
hyphen. p88–142RLeBx was derived from p88–142eBx by in-
troduction of C98R and V102L. Plasmid pSARM4, containing
a Mason–Pfizer monkey virus (MPMV) infectious molecular
clone, was provided by Eric Hunter (University of Alabama at
Birmingham, Birmingham) (11). Plasmid pG1-ZAP containing
a Moloney murine leukemia virus (M-MLV) infectious molec-
ular clone was provided by Noriyuki Kasahara (University of
California, Los Angeles).
Cell Culture and Virus Expression. 293T and HeLa cells were grown
in DMEM supplemented with 10% FBS at 37°C, 5% CO2, and
95% humidity. Virus was produced by transfection of 293T by
the CalPhos Mammalian Transfection kit (Clontech). None of
the plasmids used in this study has a simian virus 40 origin of
replication. Viral particles were collected from supernatants
of transfected cells 48 h posttransfection, and virus was con-
centrated by ultracentrifugation as described in ref. 3. For
analysis of viral proteins, cells were lysed 48 h posttransfection
following standard techniques (12).
SDSPAGE and Western Blotting. SDSPAGE and Western blotting
were performed as described in ref. 13. JSRV Gag was detected
by using rabbit polyclonal sera against JSRV p23 (13) obtained
by immunizing rabbits with a recombinant protein containing
Gag amino acid residues 1–255. MPMV Gag was detected with
goat anti-MPMV CA (a gift from Eric Hunter), and M-MLV
Gag was detected with rabbit anti-CA serum.
Reverse Transcriptase (RT) Assays. Virus in the supernatant of
transfected cells was quantified by exogenous RT assays (3).
Electron Microscopy. 293T cells were transfected with the plasmids
indicated in Results by using Lipofectamine (Invitrogen). Forty-
eight hours posttransfection, cells were fixed, dehydrated, em-
bedded, and sectioned for electron microscopy by using standard
methods.
Confocal Microscopy. Cells were grown in chamber slides coated
with polylysine and transfected with the plasmids indicated in
Results by using lipofectamine (Invitrogen). Thirty hours post-
transfection, cells were fixed in 3% paraformaldehyde and
processed essentially as described in ref. 15. Gag proteins were
detected by using rabbit anti-p23 preadsorbed with HeLa cell
extracts, followed by goat anti-rabbit IgG labeled with Alexa-488
(Molecular Probes). Nuclei were stained by using To-Pro-3
(Molecular Probes). Slides were analyzed by using a Leica TCS
SP2 confocal microscope.
RNA Extraction, RT-PCR, and Sequence Analysis. RNA from sheep
endometrium and placentomes (n  2) was isolated by using
standard procedures (12). RNA was reverse transcribed and
amplified by PCR by using primers UntrGagenf (5-AATT-
GAGGAGGAGTAGTAAGG-3, position 540 –560 of
enJS56A1) and UnivGagenr (5-CTTGATGGTATTTAG-
CAGCTTC-3, positions 1065–1044). Four independent PCR
products were cloned into pCR2.1 (Invitrogen), and 34 inde-
pendent clones were analyzed by sequencing.
Results
enJS56A1 Is Abundantly Expressed in the Cytoplasm of Transfected
Cells and Blocks JSRV Exit. enJS56A1 does not release viral parti-
cles in the supernatant of transfected 293T cells, despite the
presence of an intact gag gene and the use of the strong CMV
promoter (7). It seemed possible that Gag was not expressed
efficiently because of some transcriptional or translational de-
fect. However, Western blotting analysis of lysates of 293T cells
transfected with pCMV2en56A1 revealed abundant quantities of
immature Gag (70 kDa) (Fig. 1A). As expected, lysates ob-
tained from pCMV2JS21-transfected cells showed both the
immature and the mature form of Gag, whereas only the latter
was detectable in the supernatant.
We then determined whether enJS56A1 was able to influence
the capacity of JSRV to exit the cells in cotransfection assays.
Analysis of cell lysates from 293T cells cotransfected with
pCMV2JS21 and pCMVen56A1 indicated the presence of abun-
dant immature Gag protein in cell lysates, but no viral particles
were detected in the supernatant (Fig. 1 A, lane 3). Titration of
the amount of pCMV2enJS56A1 cotransfected with a fixed
amount of pCMV2JS21 showed that enJS56A1 can inhibit JSRV
particle release even at a 1:15 ratio (enJS56A1:JSRV plasmid
DNA) (Fig. 1B). Quantitative analysis by RT assays of particles
(data not shown) released in the supernatant of cells transfected
with pCMV2JS21 or pCMV2enJS56A1 or cotransfected with an
equal mixture of both plasmids revealed that the endogenous
enJS56A1 reduces JSRV exit by 440-fold (geometric mean of
the degree of inhibition in five independent experiments) to a
level virtually indistinguishable from the background value seen
with cells transfected with empty plasmid. Thus, the RT results
are fully consistent with the Western blotting data, confirming
the ability of enJS56A1 to block virus particle formation or exit
by JSRV. As shown in Fig. 1 A, lane 2, only the uncleaved Gag
Fig. 1. enJS56A1 specifically inhibits JSRV viral particle release. (A) Western
blot analysis of cell lysates (Left) and supernatants (Right) of 293T transfected
or cotransfected with enJS56A1 and JSRV expression plasmids. Gag was de-
tected with a JSRV p23 antiserum. Lanes: 1, JSRV; 2, enJS56A1; 3, enJS56A1
JSRV; M, mock. (B) Western blot analysis of cell lysates and supernatants of
293T cells cotransfected with fixed amounts (14 g) of JSRV expression plas-
mid and decreasing amounts of enJS56A1 expression plasmid. (C) JS21pro is
able to release viral particles in the supernatant of transfected cells. Lanes: M,
mock; 1, JS21pro; 2, JSRV. (D) enJS56A1 does not inhibit MPMV exit in
cotransfection assays. Lanes: 1, MPMV; 2, MPMVenJS56A1; M, mock. Gag
was detected with anti-MPMV CA serum. (E) enJS56A1 does not inhibit M-MLV
viral exit. Lanes: 1, M-MLV; 2, M-MLVenJS56A1; M, mock. Gag was detected
with anti-MLV CA serum.
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polyprotein is seen in lysates of enJS56A1-transfected cells. It
seemed possible that the failure of maturation cleavage in this
virus was responsible for the defect in particle release. To test
this possibility, we deleted nucleotides 2116–2147 in the pro-
tease-coding region of pJS21m (pJS21m derives from
pCMV2JS21 by removal of the multiple cloning site after the 3
long terminal repeat and introduction of an XbaI and a SalI site
in gag by silent mutagenesis). This mutation prevented cleavage
of pJS21 Gag but had no effect on particle production (Fig. 1C);
thus, inhibition of Gag cleavage cannot explain the block in viral
exit caused by enJS56A1. We also tested the ability of enJS56A1
to interfere with virus production by MPMV (another betaret-
rovirus) or M-MLV (a gammaretrovirus). As shown in Fig. 1 D
and E, enJS56A1 had no detectable effect on these viruses.
enJS56A1 Forms Intracytoplasmic Viral Particles. enJS56A1 is abun-
dantly expressed in transfected 293T cells (Fig. 1). Consequently,
we performed electron microscopy analysis to determine
whether enJS56A1 was able to form viral particles. Cells trans-
fected with JSRV expression plasmid showed, as expected,
complete extracellular particles with envelope (Fig. 2A), parti-
cles approaching and budding from the cell membrane (Fig. 2B),
and intracytoplasmic core particles (Fig. 2 C and D) typical of
betaretroviruses. Cells transfected with enJS56A1 expression
plasmid also showed intracytoplasmic viral particles more often
visible in the perinuclear region (Fig. 2 E and F), but no budding
or extracellular particles were observed, in agreement with
Western blotting and RT analysis. A difference noted between
the intracytoplasmic particles of JSRV and enJS56A1 was that
the latter were in large agglomerations of tightly packed parti-
cles. The presence of incomplete particles in these clusters
suggests that these are the sites of enJS56A1 assembly. However,
the incomplete particles may simply represent particles that have
been sectioned during sample preparation. In addition, we
noticed that enJS56A1 particles appear to have projections from
the viral core that at times seem to join particles together. These
projections could be part of the enJS56A1 Gag or could be
cellular structures linked to the enJS56A1 particles. Viral par-
ticles in cells cotransfected with both JSRV and enJS56A1
plasmids showed the same phenotype of enJS56A1 particles with
large clusters of viral particles (Fig. 2 G and H).
Thus, enJS56A1 is able to induce the formation of viral
particles that assemble in the cytoplasm, but they are not able to
reach and bud from the cell membrane. Furthermore, expression
of this endogenous genome prevents JSRV from producing virus
into the culture supernatant.
Determinants of the enJS56A1 Defect in Viral Exit and Interference
Map in Different Amino Acid Residues of the Amino-Terminal Gag.
The enJS56A1 and JSRV Gag are 94% identical. The major
differences are localized in two regions (VR1 and VR2) that are
rich in proline residues (in JSRV) and localized in Gag between
the putative MA and CA proteins (7, 13), probably in p23 (the
exact boundaries of the JSRV Gag proteins are not known with
certainty). To map the determinants of the defect of viral exit
and interference of enJS56A1, a panel of chimeras between
JSRV and enJS56A1 was constructed, and their ability to exit
transfected cells and interfere with JSRV was determined.
The schematic representation of the chimeras, the relative
position of the restriction sites used for the molecular cloning,
and the results obtained in transfection assays are shown in Fig.
3. The results of these tests can be summarized briefly as follows.
The defect in virus production of enJS56A1, and its ability to
interfere with JSRV virus production, can be attributed to amino
acids in Gag proximal to residue 142. The VR1 per se is not
responsible for the defect of enJS56A1 because chimeras p88–
142ebBx and p88–142ecBx, containing, respectively, the VR1
from loci enJS5F16 and enJS59A1, were able to exit transfected
cells (data not shown). However, a chimera with residues 88–142
from enJS56A1 (p88–142eBx) was defective, but the defect
could be reversed by the two mutations C98R and V102L.
Interestingly, p88–142eBx can be rescued by WT JSRV, and it
can complement a protease-defective JSRV, leading to the
production of particles with Gag cleavage products (data not
shown). Thus, C98 andor V102 of enJS56A1 block its ability to
produce virus into the supernatant, but this defect is recessive in
the presence of WT Gag (Fig. 3).
To further define the residues responsible for the defects in
enJS56A1, we constructed a series of point-mutants of JSRV
(Table 1). We found that mutants pJSR98C and pJSR98C-
L102V did not release particles but did not interfere with WT
JSRV production. In contrast, mutant pJSR21W replicated the
phenotype of enJS56A1, failing to produce virus and interfering
Fig. 2. enJS56A1 assembles intracytoplasmic viral particles. 293T cells were
transfected with JSRV (A–D) or enJS56A1 (E and F) or cotransfected (G and H)
with both expression plasmids and analyzed by electron microscopy. (A and B)
Extracellular complete JSRV particles and particles approaching and budding
from the membrane. (C and D) Intracytoplasmic JSRV. (E and F) enJS56A1
particles. (C and F) Arrows, incomplete viral particles. In E, arrows point to
apparent projections from the enJS56A1 particles. (G and H) Large clusters of
perinuclear viral particles in enJS56A1JSRV cotransfected cells. N, nucleus.
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with JSRV production (Fig. 4A). Tests on these and other
mutants lead to the conclusion that the critical mutation of the
arginine residue at position 21 of JSRV into a tryptophan in
enJS56A1 determines the dominant negative functions of the
endogenous Gag. Mutations R98C and L102V are also respon-
sible for additional defects in viral exit that by themselves are not
dominant, although they decrease the amount of viral particles
released by the cotransfected JSRV.
We also tested whether by affecting the myristoylation signal
we would create mutants that are unable to exit and are
transdominant over WT JSRV. Both single mutant pJS21G2A
and triple mutant pJS21G2A-R98C-L102V were unable to re-
lease viral particles in the supernatant as expected; however, they
did not interfere significantly with the exit of JSRV (Fig. 4). This
finding suggests that R21 does not simply affect the efficacy of
membrane targeting by the myristoylation signal.
Correction of enJS56A1 Defect in Viral Particle Release. Endogenous
mutants pen56W21R and pen56W21R-V102L did not render
enJS56A1 capable of releasing viral particles in the supernatant
of transfected cells. However, double mutant pen56W21R-C98R
did restore the capacity of enJS56A1 to exit transfected cells. The
level of expression of en56W21R-C98R was in general lower
than that of the WT JSRV (Fig. 4B).
Confocal Microscopy. We next analyzed the pattern of expression
of JSRV, enJS56A1, and the relevant mutants by confocal
microscopy using a JSRV p23 antiserum (Fig. 5). We classified
Gag-positive cells into three basic phenotypes: (i) diffuse, (ii)
dispersed, and (iii) concentrated. Cells with a diffuse phenotype
had a uniform cytoplasmic staining, usually more intense in the
perinuclear region. In the dispersed phenotype, ‘‘dots’’ of fluo-
rescence were visible and scattered in the cytoplasm, whereas in
the concentrated phenotype, there was an area of intense
staining in the vicinity of the nucleus. These terms are in accord
with recent descriptions of cells expressing the betaretrovirus
MPMV, which is assembled in the pericentriolar region of the
cell (15). Most often, cells presented a mixed diffused-dispersed
phenotype that we counted as dispersed. There were no signif-
icant differences in the distribution of the three phenotypes
among enJS56A1, JSRV, and JSR21W (Fig. 5) in three inde-
pendent experiments. However, cells transfected with enJS56A1
always presented the highest number of Gag-positive cells and
the most intense staining, consistent with the inability of this Gag
to be released from the cell. In addition, the ‘‘dispersed’’ foci of
f luorescence in cells expressing enJS56A1 were much larger than
those observed with JSRV or any other mutant. We expected
cells cotransfected with JSRV and enJS56A1 expression plas-
mids to resemble enJS56A1-positive cells, given the dominant-
negative property of its Gag; however, they showed mainly a
diffuse phenotype with intense perinuclear staining. JS21R98C
and JS21G2A consistently showed the highest proportion of cells
with a concentrated phenotype. The fact that the phenotypes of
the R98C and R21W mutants are different suggests that W21
and C98 contribute in different ways to the defects in enJS56A1.
Confocal microscopy confirms what we have seen by electron
microscopy: enJS56A1 (and defective mutants) do not accumu-
Fig. 3. Determinants of enJS56A1 defect in viral exit and interference. (A)
Schematization of the first 344 Gag amino acid residues. The restriction sites
used for the construction of the chimeras, the VR1–VR2 regions, and the amino
acid residues found to be critical for the enJS56A1 defect are indicated.
enJS59A1 has a premature stop codon in gag upstream of position 88; amino
acid residue at position 21 is indicated by *. (B) Schematic representation of
the chimeras constructed in this study and results obtained in transfection and
cotransfection assays.
Table 1. Phenotypes of JSRV mutants
Mutant Exit Interference
pJSL102V Yes n.a.
pJSR98C No No
pJS21R21W No Yes
pJSG2A No No
pJSR98C-L102V No No
pJSR21W-R98C-L102V No Yes
pJSG2A-R98C-L102V No No
pJSG2V-R21W-R98C-L102V No Yes
n.a., not applicable.
Fig. 4. Western blotting analysis of JSRV and enJS56A1 mutants. Superna-
tants (Upper) and cell lysates (Lower) of 293T cells cotransfected with JSRV and
critical mutant expression plasmids were analyzed by Western blotting for the
presence of Gag proteins. (A) Lanes: 1, JSRV; 2, JSRV JSG2A; 3, JSRVJSR21W;
4, JSRV  JSR98C-L102V; 5, JSRV  JSG2A-R98C-L102V; 6, JSRV  JSR21W-
R98C-L102V; 7, JSRV  JSG2V-R21W-R98C-L102V; 8, JSRV  JSR98C. (B) Res-
toration of enJS56A1 viral exit. Lanes: M, mock; 1, en56W21R-V102L; 2,
en56W21R-C98R; 3, en56W21R. Note that the p23 of the endogenous Gag has
a slightly lower molecular weight with respect to the homologous JSRV
protein, probably because of the lack of proline residues in the VR1 and VR2
regions of the endogenous locus.
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late at the cell membrane. As shown by electron microscopy, the
enJS56A1 particles seem to be present mainly in the perinuclear
region, suggesting that the cytoplasmic staining in the dispersed
and diffuse phenotype observed by confocal microscopy prob-
ably derives from nonparticulate Gag proteins.
Overall, these data suggest that the defect possessed by
enJS56A1 seems to be at the level of viral particle trafficking
between the cytoplasm and the cell membrane.
enJS56A1 Is Expressed in the Sheep Uterus. enJSRVs RNA and
proteins are highly expressed in the sheep uterus (5–7). How-
ever, there are 20 copies of enJSRV loci, and no information
is available on their relative expression levels. The critical R21W
mutation of enJS56A1 is not present in the other two published
full-length enJSRVs sequences, enJS5F16 and enJS59A1 (7). We
performed RT-PCR on sheep endometrium by amplifying a
region between the 5 leader and the VR2 region of Gag. Primers
were chosen in regions highly conserved between enJSRVs and
JSRV sequences to amplify as many enJSRV loci as possible.
Four independent PCRs were cloned into a PCR cloning vector,
and 34 independent clones were fully sequenced. Sequence
analysis revealed that 12 sequences of the 34 clones had some
defect in the gag gene that would preclude production of
functional protein (e.g., premature stop codons, frame shifts, or
mutations in the first ATG). Of the remaining 22 clones with an
intact gag ORF, 4 had the critical W21, C98, and V102 mutations
characteristic of the enJS56A1 clone. These data suggest that
enJS56A1 (or enJS56A1-like loci) is expressed in the sheep
endometrium.
Discussion
In this paper, we have described an endogenous retrovirus of
sheep (enJS56A1) with a dominant negative Gag protein that
interferes with its exogenous counterpart (JSRV) at a postas-
sembly level. This blockade represents a previously uncharac-
terized mechanism of retroviral interference. The other known
ERV-mediated blocks are all at early stages of the retroviral
replication cycle such as entry (by receptor competition) or at a
preintegration step (Fv-1) (1).
JSRVenJSRVs are betaretroviruses, and thus they assemble
in the cytoplasm. Cells expressing enJS56A1 (or coexpressing
enJS56A1 and JSRV) display large clusters of tightly packed
particles in the cytoplasm. The almost regular organization of the
enJS56A1 particles, and the presence in these groupings of
incomplete cores, suggests that assembled particles are not able
to traffic properly to the cell membrane.
The tryptophan residue at position 21 of the enJS56A1 MA
(replacing an arginine in JSRV) is the main determinant for the
block induced by enJS56A1, although C98 and V102 contribute
to the overall dominant negative activity of the endogenous Gag.
The mutant JSR21W shows a dominant negative phenotype
analogous to enJS56A1. Interestingly, R21 (and a glycine residue
immediately after) is conserved in all betaretroviruses, including
MPMV and related simian betaretroviruses, mouse mammary
tumor virus, and human endogenous retrovirus-K. The JSRV
enJS56A1 MAs and MPMV MA are 39% identical and 64%
similar, and this level of similarity allows for structural modeling
on the basis of the homologous MPMV protein (16, 17) (Fig. 6).
R21 falls at the end of the first -helix of MA. Thus, the R to W
mutation present in the enJS56A1 introduces a hydrophobic
amino acid in an exposed portion of the protein. This noncon-
servative mutation could alter the ability of Gag to interact with
cellular factors necessary for the trafficking of viral particles,
although it is also possible that the mutation exerts its effects by
altering the structure or assembly properties of Gag. The ad-
Fig. 5. Confocal microscopy of HeLa cells expressing or coexpressing
enJS56A1, JSRV, and critical mutants. Positive cells have been quantified
according to three phenotypes: diffuse (Diff.), dispersed (Disp.), and concen-
trated (Conc.). At the top is the quantification of a representative experiment.
Values indicate relative percentage of each phenotype, and the last column
indicates the total number of cells counted for each transfection. Photomi-
crographs are representative examples of cells expressing the indicated viruses
and mutants. Note that the ‘‘dispersed’’ phenotype for enJS56A1-transfected
cells consists of larger foci with a more intense fluorescence than in other
samples. Gag staining is in green, and nuclei are in red or with the letter N.
Fig. 6. Modeling of the putative JSRV and enJS56A1 MA proteins. The
tertiary structures of the matrix proteins of enJS56A1 and JSRV were modeled
by using the Swiss Model Server (http:swissmodel.expasy.org). The matrix
protein of MPMV (Protein Data Bank ID code 1BAX) was used as a template.
As the available MPMV matrix protein structure at the Protein Data Bank is a
carbon trace structure, a tertiary structure including side chains was generated
by using the MaxSprout database algorithm (www.ebi.ac.ukmaxsprout).
Models are displayed in ribbons, and the W21 and R21 are displayed in green
in a ball-and-stick format. The N and C terminals are indicated. The first-helix
is shown in blue. Both models were derived from the amino-terminal 92-aa
residues of the JSRVenJS56A1 Gag.
Mura et al. PNAS  July 27, 2004  vol. 101  no. 30  11121
M
IC
RO
BI
O
LO
G
Y
mixture of mutant Gag protein blocks the transport of assembled
particles containing WT Gag; thus, it appears that the normal
trafficking of WT particles to the plasma membrane depends on
the concerted action of many WT Gag molecules. The myris-
toylation signal plays a critical role in targeting Gag and viral
particles to the cell membrane (18, 19). Mutation of the myris-
toylation signal did not confer a dominant negative phenotype to
the resulting mutant (JSG2A) but did block viral exit. However,
a polybasic region downstream of the myristoylation signal in
other retroviruses also has been found to be an important signal
for membrane targeting of Gag (20). It is possible that the R21W
mutation impairs membrane-targeting of JSRV Gag. Another
class of mutants that interferes with release of assembled virions
is the ‘‘late (L) domain’’ mutants. However, it seems unlikely that
enJS56A1 is equivalent to an L domain mutant because such
mutants of MPMV accumulate at the cell membrane (21, 22) and
enJS56A1 still contains intact PSAP and PPXY motifs in its VR2
region.
The agglomerates of viral particles visible in JSRVenJS56A1
transfected cells resemble ‘‘viral factories’’ of large DNA viruses
such as poxviruses, iridoviruses, and asfaviruses (23). These viral
factories have been shown to have similar properties to the
aggresomes, perinuclear cellular sites where misfolded or unas-
sembled proteins are transported and sequestered by the cell.
Aggresomes are localized in the vicinity of the centrosomes and
enclosed in a characteristic vimentin cage (24). It will be
interesting to determine whether JSRV andor enJS56A1 as-
sembly takes place in these cellular structures.
The exact biological role of the enJS56A1 locus in the
evolutionary interplay with its exogenous counterpart and its
host is difficult to establish. By RT-PCR, we determined that
enJS56A1 (or similar loci containing W21, C98, and V102) are
expressed in the sheep endometrium. We have previously shown
that enJSRVs also can interfere with JSRV entry by receptor
competition (9). Thus, enJSRVs have developed a two-step
strategy and are capable of interfering in the replication cycle of
related exogenous viruses at both early and late stages. Alter-
natively, or additionally, enJS56A1 might have been used by the
host to ‘‘control’’ the replication of other enJSRVs with some
damaging effect.
In conclusion, these studies have shown previously uncharac-
terized interfering properties of an endogenous retroviral Gag.
Understanding the molecular mechanisms underlying the
enJS56A1-induced block could spark new strategies for obtain-
ing antiretroviral drugs. This study provides a previously un-
characterized example of an endogenous retrovirus with a
dominant negative Gag protein that acts at a late step of the viral
replication cycle. HIV Gag mutants with dominant negative
effects have been derived in the late 1980s and early 1990s (14,
25), along with the hope of an effective ‘‘intracellular immuni-
zation’’ (14). Our results suggest that this phenomenon has,
in fact, arisen in sheep as a result of natural selection. The
exogenous counterpart of enJS56A1, JSRV, causes a major
infectious disease of sheep with no available vaccine. The recent
development of animal cloning technologies raises the possibility
that a transgenic sheep in which enJS56A1 expression is directed
to the differentiated epithelial cells of the lungs, the cells’ target
for JSRV transformation, would be resistant to JSRV-induced
disease. Thus, the JSRV-enJS56A1 system could furnish a
unique model to test the intracellular immunization theory in a
naturally occurring retroviral infection.
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